Challenges in treating older patients with acute myeloid leukemia

Journal of Oncology

Volumn , Issue , 2010, Pages

  Alexandros, Spyridonidis ^a   Eleni, Lagadinou D ^a   Nicholas, Zoumbos C ^a  

^a UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; 5 AZACITIDINE; AZACITIDINE; CLOFARABINE; CLORETAZINE; CYCLOSPORIN; CYTARABINE; DAUNORUBICIN; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HYDROXYUREA; IDARUBICIN; LESTAURTINIB; MIDOSTAURIN; PLERIXAFOR; TIPIFARNIB; UNCLASSIFIED DRUG; VALSPODAR; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RISK; CHROMOSOME ABERRATION; CLINICAL FEATURE; COMMUNICATION SKILL; COMORBIDITY; CYTOGENETICS; DECISION MAKING; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FUNCTIONAL STATUS; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTENSIVE CARE; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; NEUTROPENIA; NONHUMAN; PATIENT INFORMATION; PROGNOSIS; QUALITY OF LIFE; REVIEW; SOCIAL BACKGROUND; THROMBOCYTOPENIA; TREATMENT PLANNING;

EID: 77954628885     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2010/943823     Document Type: Review

References (99)

1. Sekeres M. A., Stone R. M., Zahrieh D., Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome Leukemia 2004 18 4 809 816
2. Menzin J., Lang K., Earle C. C., Kerney D., Mallick R., The outcomes and costs of acute myeloid leukemia among the elderly Archives of Internal Medicine 2002 162 14 1597 1603
3. Behringer B., Pitako J. A., Kunzmann R., Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study Annals of Hematology 2003 82 7 381 389
4. Pulsoni A., Pagano L., Latagliata R., Survival of elderly patients with acute myeloid leukemia Haematologica 2004 89 3 296 302
5. Estey E. H., Treatment of acute myeloid leukemia Haematologica 2009 94 1 10 16
6. Hiddemann W., Kern W., Schoch C., Management of acute myeloid leukemia in elderly patients Journal of Clinical Oncology 1999 17 11 3569 3576 (Pubitemid 29517929)
7. Klepin H. D., Balducci L., Acute myelogenous leukemia in older adults Oncologist 2009 14 3 222 232
8. Leith C. P., Kopecky K. J., Godwin J., Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group Study Blood 1997 89 9 3323 3329
9. Fialkow P. J., Singer J. W., Raskind W. H., Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia The New England Journal of Medicine 1987 317 8 468 473
10. Wilson C. S., Davidson G. S., Martin S. B., Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction Blood 2006 108 2 685 696
11. Ferrara F., Pinto A., Acute myeloid leukemia in the elderly: current therapeutic results and perspectives for clinical research Reviews on Recent Clinical Trials 2007 2 1 33 41
12. Cheson B. D., Jasperse D. M., Simon R., Friedman M. A., A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes Journal of Clinical Oncology 1986 4 12 1857 1864
13. Burnett A. K., Milligan D., Prentice A. G., A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment Cancer 2007 109 6 1114 1124
14. Wahlin A., Hornsten P., Jonsson H., Remission rate and survival in acute myeloid leukemia: impact of selection and chemotherapy European Journal of Haematology 1991 46 4 240 247
15. Frhling S., Schlenk R. F., Kayser S., Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B Blood 2006 108 10 3280 3288
16. Prebet T., Boissel N., Reutenauer S., Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup Journal of Clinical Oncology 2009 27 28 4747 4753
17. Breems D. A., Van Putten W. L. J., de Greef G. E., Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype Journal of Clinical Oncology 2008 26 29 4791 4797
18. O'Donnell M. R., Appelbaum F. R., Baer M. R., Acute myeloid leukemia: clinical practice guidelines in oncology Journal of the National Comprehensive Cancer Network 2006 4 1 16 36
19. Morra E., Barosi G., Bosi A., Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice Guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation Haematologica 2009 94 1 102 112
20. Grimwade D., Walker H., Harrison G., The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial Blood 2001 98 5 1312 1320
21. Gupta V., Chun K., Yi Q.-L., Disease biology rather than age is the most important determinant of survival of patients ≥60 years with acute myeloid leukemia treated with uniform intensive therapy Cancer 2005 103 10 2082 2090
22. Buchner T., Berdel W. E., Haferlach C., Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the german acute myeloid leukemia cooperative group Journal of Clinical Oncology 2009 27 1 61 69
23. Schlenk R. F., Dhner K., Kneba M., Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B Haematologica 2009 94 1 54 60
24. Sekeres M. A., Elson P., Kalaycio M. E., Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients Blood 2009 113 1 28 36
25. Appelbaum F. R., Gundacker H., Head D. R., Age and acute myeloid leukemia Blood 2006 107 9 3481 3485
26. Kantarjian H., O'Brisn S., Cortes J., Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome Cancer 2006 106 5 1090 1098
27. Malfuson J.-V., Etienne A., Turlure P., Risk factors and decision criteria for intensive chemotherapy in older patients with acute myeloid leukemia Haematologica 2008 93 12 1806 1813
28. Lowenberg B., Zittoun R., Kerkhofs H., On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group Journal of Clinical Oncology 1989 7 9 1268 1274
29. Juliusson G., Antunovic P., Derolf., Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry Blood 2009 113 18 4179 4187
30. Bchner T., Hiddemann W., Berdel W., Acute myeloid leukemia: treatment over 60 Reviews in Clinical and Experimental Hematology 2002 6 1 46 59
31. Rees J. K. H., Gray R. G., Wheatley K., Dose intensification in acute myeloid leukaemia: greater effectiveness at lower cost. Principal report of the Medical Research Council's AML9 study British Journal of Haematology 1996 94 1 89 98
32. Lowenberg B., Ossenkoppele G. J., van Putten W., High-dose daunorubicin in older patients with acute myeloid leukemia The New England Journal of Medicine 2009 361 13 1235 1248
33. Weick J. K., Kopecky K. J., Appelbaum F. R., A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study Blood 1996 88 8 2841 2851
34. Buchner T., Hiddemann W., Berdel W. E., 6-Thioguanine, cytarabine, and daunorubicin (TAD) and high-dose cytarabine and mitoxantrone (HAM) for induction, TAD for consolidation, and either prolonged maintenance by reduced monthly TAD or TAD-HAM-TAD and one course of intensive consolidation by sequential HAM in adult patients at all ages with de novo acute myeloid leukemia (AML): a randomized trial of the German AML Cooperative Group Journal of Clinical Oncology 2003 21 24 4496 4504
35. Schiller G., Lee M., Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for older patients with acute myelogenous leukemia Leukemia and Lymphoma 1997 25 1-2 111 119
36. Reiffers J., Huguet F., Stoppa A.-M., A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75 Leukemia 1996 10 3 389 395
37. Tallman M. S., Gilliland D. G., Rowe J. M., Drug therapy for acute myeloid leukemia Blood 2005 106 4 1154 1163
38. Miyauchi J., Kelleher C. A., Wang C., Minkin S., McCulloch E. A., Growth factors influence the sensitivity of leukemic stem cells to cytosine arabinoside in culture Blood 1989 73 5 1272 1278
39. Amadori S., Suciu S., Jehn U., Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study Blood 2005 106 1 27 34
40. Dombret H., Chastang C., Fenaux P., A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia The New England Journal of Medicine 1995 332 25 1678 1683
41. Milligan D. W., Wheatley K., Littlewood T., Craig J. I. O., Burnett A. K., Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial Blood 2006 107 12 4614 4622
42. Wheatley K., Goldstone A. H., Littlewood T., Hunter A., Burnett A. K., Randomized placebo-controlled trial of granulocyte colony stimulating factor (G-CSF) as supportive care after induction chemotherapy in adult patients with acute myeloid leukaemia: a study of the United Kingdom Medical Research Council Adult Leukaemia Working Party British Journal of Haematology 2009 146 1 54 63
43. Nervi B., Ramirez P., Rettig M. P., Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100 Blood 2009 113 24 6206 6214
44. Uy G. L., Rettig M. P., Mcfarland K. M., Mobilization and chemosensitization of AML with the CXCR4 antagonist plerixafor (AMD3100): a phase I/II study of AMD3100+MEC in patients with relapsed or refractory disease Blood 2008 112 11. abstract 1944
45. Matsouka P., Pagoni M., Zikos P., Addition of cyclosporin-A to chemotherapy in secondary (post-MDS) AML in the elderly. A multicenter randomized trial of the Leukemia Working Group of the Hellenic Society of Hematology Annals of Hematology 2006 85 4 250 256
46. List A. F., Kopecky K. J., Willman C. L., Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study Blood 2001 98 12 3212 3220
47. Greenberg P. L., Lee S. J., Advani R., Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995) Journal of Clinical Oncology 2004 22 6 1078 1086
48. Erba H. P., Prognostic factors in elderly patients with AML and the implications for treatment Hematology 2007 420 428
49. Burnett A. K., Milligan D., Goldstone A., The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial British Journal of Haematology 2009 145 3 318 332
50. Cripe L. D., Li X., Litzow M., A randomized, placebocontrolled, double blind trial of the MDR modulator zosuquidar, during conventional induction and postremission therapy for pts 60 years of age with newlydiagnosed acute myeloid leukemia (AML) or high risk myelodysplastic syndrome (HR-MDS): ECOG 3999 Blood 2006 108, article 129a
51. Burnett A. K., Baccarani M., Johnson P., Yin J., Russell N., Clofarabine in previously untreated elderly ( 65 yrs) AML patients with an unfavourable cytogenetic profile who are considered unfit for standard intensive chemotherapy Blood 2006 24 18S. abstract 6513
52. Erba H. P., Kantarjian H. M., Claxton D., Phase II study of single agent clofarabine in previously untreated older adult patients with acute myelogenous leukemia (AML) unlikely to benefit from standard induction chemotherapy Journal of Clinical Oncology 2008 20S. abstract 7025
53. Faderl S., Ravandi F., Huang X., A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome Blood 2008 112 5 1638 1645
54. Karp J. E., Rizzieri D., Vey N., Cloretazine is an effective induction therapy in elderly patients (pts) with poor-risk de novo AML Journal of Clinical Oncology 2006 24 18S
55. Karp J. E., Rizzieri D., Vey N., Cloretazine is an effective induction therapy in elderly patients (pts) with poor-risk de novo AML Journal of Clinical Oncology 2006 24 18S
56. Daskalakis M., Nguyen T. T., Nguyen C., Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-aza- 2′ -deoxycytidine (decitabine) treatment Blood 2002 100 8 2957 2964
57. Kaminskas E., Farrell A., Abraham S., Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes Clinical Cancer Research 2005 11 10 3604 3608
58. Fenaux P., Mufti G. J., Hellstrom-Lindberg E., Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study The Lancet Oncology 2009 10 3 223 232
59. Fenaux P., Mufti G. J., Hellstrm-Lindberg E., Azacitidine prolongs overall survival (OS) and reduces infections and hospitalizations in patients (Pts) with WHO-defined acute myeloid leukemia (AML) compared with conventional care regimens (CCR) Blood 2008 112. abstract 3636
60. Ravandi F., Issa J.-P., Garcia-Manero G., Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities Cancer 2009 115 24 5746 5751
61. Lubbert M., Ruter B., Claus R., Continued low-dose decitabine (DAC) is an active first-line treatment in all cytogenetic subgroups of older AML patients: results of the FR00331 multicenter phase II study Blood 2007 110 95a. abstract 300
62. Larson R. A., Sievers E. L., Stadtmauer E. A., Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence Cancer 2005 104 7 1442 1452
63. Doyen J., Italiano A., Peyrade F., Bouyer C., Thyss A., Gemtuzumab ozogamicin plus cytarabine in elderly patients with relapsed or refractory acute myeloid leukaemia British Journal of Haematology 2008 141 5 744 745
64. Fianchi L., Pagano L., Leoni F., Gemtuzumab ozogamicin, cytosine arabinoside, G-CSF combination (G-AraMy) in the treatment of elderly patients with poor-prognosis acute myeloid leukemia Annals of Oncology 2008 19 1 128 134
65. Amadori S., Suciu S., Willemze R., Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups Haematologica 2004 89 8 950 956
66. Clavio M., Vignolo L., Albarello A., Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients British Journal of Haematology 2007 138 2 186 195
67. Nand S., Godwin J., Smith S., Hydroxyurea, azacitidine and gemtuzumab ozogamicin therapy in patients with previously untreated non-M3 acute myeloid leukemia and high-risk myelodysplastic syndromes in the elderly: results from a pilot trial Leukemia and Lymphoma 2008 49 11 2141 2147
68. Harousseau J.-L., Martinelli G., Jedrzejczak W. W., A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older Blood 2009 114 6 1166 1173
69. Knapper S., Burnett A. K., Littlewood T., A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy Blood 2006 108 10 3262 3270
70. Deeg H. J., Shulman H. M., Anderson J. E., Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age Blood 2000 95 4 1188 1194
71. Du W., Dansey R., Abella E. M., Successful allogeneic bone marrow transplantation in selected patients over 50 years of agea single institution's experience Bone Marrow Transplantation 1998 21 10 1043 1047
72. Bertz H., Potthoff K., Finke J., Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia Journal of Clinical Oncology 2003 21 8 1480 1484
73. Estey E., de Lima M., Tibes R., Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) Blood 2007 109 4 1395 1400
74. Finke J., Nagler A., Viewpoint: what is the role of allogeneic haematopoietic cell transplantation in the era of reduced-intensity conditioningis there still an upper age limit? A focus on myeloid neoplasia Leukemia 2007 21 7 1357 1362
75. Hegenbart U., Niederwieser D., Sandmaier B. M., Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors Journal of Clinical Oncology 2006 24 3 444 453
76. Ho A. Y. L., Pagliuca A., Kenyon M., Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning Blood 2004 104 6 1616 1623
77. Kroger N., Bornhuser M., Ehninger G., Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia Annals of Hematology 2003 82 6 336 342 (Pubitemid 36806015)
78. Maris M. B., Niederwieser D., Sandmaier B. M., HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies Blood 2003 102 6 2021 2030
79. Marks R., Potthoff K., Hahn J., Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies Blood 2008 112 2 415 425
80. Mohty M., de Lavallade H., El-Cheikh J., Reduced intensity conditioning allogeneic stem cell transplantation for patients with acute myeloid leukemia: long term results of a donor versus no donor comparison Leukemia 2009 23 1 194 196
81. Ringden O., Labopin M., Ehninger G., Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia Journal of Clinical Oncology 2009 27 27 4570 4577
82. Shimoni A., Krger N., Zabelina T., Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age 55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning Leukemia 2005 19 1 7 12
83. Slavin S., Nagler A., Naparstek E., Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91 3 756 763
84. Spyridonidis A., Bertz H., Ihorst G., Grllich C., Finke J., Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (≥60 years) with active myeloid malignancies Blood 2005 105 10 4147 4148
85. Wong R., Giralt S. A., Martin T., Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years Blood 2003 102 8 3052 3059
86. Schmid C., Schleuning M., Ledderose G., Tischer J., Kolb H.-J., Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome Journal of Clinical Oncology 2005 23 24 5675 5687
87. Russell N. H., Byrne J. I., Robinson S. P., Defining conditioning regimens for BMT-recognition of regimens of intermediate intensity Biology of Blood and Marrow Transplantation 2009 15 7 890 891
88. de Lima M., Anagnostopoulos A., Munsell M., Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation Blood 2004 104 3 865 872
89. Shimoni A., Hardan I., Shem-Tov N., Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: The role of dose intensity Leukemia 2006 20 2 322 328
90. de Lima M., Couriel D., Thall P. F., Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS Blood 2004 104 3 857 864
91. Casper J., Knauf W., Kiefer T., Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation Blood 2004 103 2 725 731
92. Petersen F. B., Ford C. D., Maximum supportive care, standard conditioning and allogeneic stem cell transplantation for elderly patients with acute myelogenous leukemia Current Opinion in Oncology 2009 21 supplement 1 S7 S9
93. Flowers M. E. D., Traina F., Storer B., Serious graft-versus-host disease after hematopoietic cell transplantation following nonmyeloablative conditioning Bone Marrow Transplantation 2005 35 3 277 282 (Pubitemid 40268300)
94. Schetelig J., Bornhuser M., Schmid C., Matched unrelated or matched sibling donors result in comparable survival after allogeneic stem-cell transplantation in elderly patients with acute myeloid leukemia: a report from the cooperative German transplant study group Journal of Clinical Oncology 2008 26 32 5183 5191
95. Sayer H. G., Krger M., Beyer J., Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: Disease status by marrow blasts is the strongest prognostic factor Bone Marrow Transplantation 2003 31 12 1089 1095
96. Anderson J. E., Gooley T. A., Schoch G., Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy Blood 1997 89 7 2578 2585
97. Jabbour E., Giralt S., Kantarjian H., Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia Cancer 2009 115 9 1899 1905
98. de Lima M., Silva L. D. P., Giralt S., Maintenance therapy with low-dose azacitidine (AZA) after allogeneic hematopoietic stem cell transplantation (HSCT) for relapsed AML or MDS: a dose and schedule finding study Blood 2008 112 11. abstract 1134
99. Sorror M. L., Maris M. B., Storer B., Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities Blood 2004 104 4 961 968 (Pubitemid 39038014)